Experimental drug can reduce symptoms of inflammatory bowel disease in pre-clinical models

A new study of mice and lab-grown human colon "organoids" indicates that an experimental drug developed by Johns Hopkins Medicine researchers can substantially reduce symptoms of inflammatory bowel disease (IBD) in pre-clinical models.

Related Keywords

Johns Hopkins University ,Maryland ,United States ,National Institutes Of Health ,Baltimore ,Americans ,Barbara Slusher ,Lily Ramsey ,Shinji Sakamoto ,Vijayabhaskar Veeravalli ,Lukas Tenora ,Christine Mcdonald ,Pavel Majer ,Arindom Pal ,Andras Ponti ,Xiaolei Zhu ,Ajit Thomas ,Manisha Pradhan ,Lauren Norris ,Diane Peters ,Johns Hopkins University School Of Medicine ,Slusher Lab ,Us Centers For Disease ,Crohn Colitis Foundation ,Johns Hopkins Medicine ,Disease Control ,Science Translational ,Johns Hopkins Drug Discovery ,Johns Hopkins University School ,Rana Rais ,Johns Hopkins Drug ,Colitis Foundation ,National Institutes ,Blackbird Laboratories ,Blackbird Labs ,Abdominal Pain ,Bleeding ,Hronic ,Crohn 39s Disease ,Drug Discovery ,Efficacy ,Nzyme ,Immune System ,Inflammation ,Inflammatory Bowel Disease ,Medicine ,Eurology ,Rganoids ,Rain ,Mh ,Protein ,Ulcerative Colitis ,